Strategic partnerships Abolis has recent and high-profile partnership activity with EuroAPI UK, L’Oréal, Evonik, HealthTech Bio Actives, and strategic investors. This indicates openness to collaborative manufacturing, co-development, and supply-chain integration opportunities that you can leverage to propose joint solutions, especially in beauty, healthtech, and sustainability-focused subsectors.

Sustainability demand The company emphasizes transforming manufacturing with renewable raw materials, secure supply chains, and greenhouse gas reductions. This positions Abolis as a fit for clients seeking sustainable, biology-driven production. Sales plays should target brands and manufacturers with explicit sustainability targets in cosmetics, food, chemicals, and healthcare.

Industrial scale With a 66+ strong team and a focus on tailor-made industrial solutions using micro-organisms, Abolis is positioned for scale-up collaborations and pilot-to-commercial programs. Propose end-to-end services from R&D through manufacturing to help clients accelerate time-to-market for biologically derived ingredients.

Tech-forward The tech stack includes cloud and open-source tooling, data-enabled processes, and modern infrastructure, suggesting readiness for digitalized bioprocess development and manufacturing. Upsell opportunities exist in data analytics, process optimization, and scalable fermentation workflows for faster, cost-efficient production.

Diverse end-markets Abolis targets multiple industries—food, healthcare, cosmetics, chemicals—through tailor-made micro-organism solutions. This breadth offers cross-sector selling opportunities to provide customized biotechnological ingredients or processes for each vertical, aligned with client sustainability and supply-security goals.